ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

REVBW Revelation Biosciences Inc

0.0156
-0.0003 (-1.89%)
Jun 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 19,357
Bid Price 0.0113
Ask Price 0.0188
News (1)
Company Name Stock Ticker Symbol Market Type
Revelation Biosciences Inc REVBW NASDAQ Equity Warrant
  Price Change Change Percent Stock Price Last Traded
-0.0003 -1.89% 0.0156 19:50:00
Open Price Low Price High Price Close Price Prev Close
0.0188 0.0127 0.0188 0.0156 0.0159
Trades Volume VWAP Dollar Volume Avg Volume
81 19,357  0.0144111  279 -
Last Trade Time Type Quantity Stock Price Currency
16:00:00 3  0.0127 USD

Revelation Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
125.94k 6.30M - 0 -120k -0.02 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Revelation Biosciences

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No REVBW Message Board. Create One! See More Posts on REVBW Message Board See More Message Board Posts

REVBW Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Your Recent History

Delayed Upgrade Clock